Refractory Overactive Bladder: How to Select 3rd Line Therapies and Optimize Outcomes Webcast (2023)
Upon completion, participants will be familiar with third-line therapies available to treat refractory overactive bladder (OAB), including the pros and cons of each option, the current data regarding outcomes to facilitate proper patient counseling and optimal techniques to maximize the success of the various therapies. The case-based format will provide real-world scenarios by which to learn about the implementation of successful third-line options. The course will provide some dedicated focus to tips and tricks regarding the technical aspects of these options and the logistical implementation of them into a busy practice.
Independent educational grant support provided by:
- Urovant Sciences, Inc.
At the conclusion of this activity, participants will be able to:
- Describe the various third-line therapies available to treat refractory OAB and discuss the pros and cons of each of the third-line therapies available to treat refractory OAB.
- Explain the current data regarding outcomes of percutaneous tibial nerve stimulation, onabotulinumtoxinA and sacral neuromodulation for treatment of refractory OAB.
- Outline how to perform percutaneous tibial nerve stimulation.
- Report how to perform onabotulinumtoxinA injections in the office or outpatient setting.
- Review techniques in optimal lead placement for sacral neuromodulation, programming and troubleshooting.
|Name||Company Name||Relationship Type||End Date|
|David Alan Ginsberg, MD||Procept||Scientific Study or Trial||9/20/2022|
|Urovant||Consultant or Advisor||12/2/2021|
|Urovant||Scientific Study or Trial||12/31/2022|
|Caldera||Consultant or Advisor||Current|
|Avation||Consultant or Advisor||9/17/2022|
|Medtronic||Meeting Participant or Lecturer||9/20/2022|
|Sandip Prasan Vasavada, MD||Allergan||Consultant or Advisor||12/31/2021|
|Medtronic||Meeting Participant or Lecturer||Current|
|Axonics||Consultant or Advisor||1/3/2022|
|BlueWind||Data safety monitoring clinical events committee||Current|
|Astellas||Consultant or Advisor||1/1/2022|
|BlueWind||Consultant or Advisor||Current|
|Kathleen Chizuko Kobashi, MD, MBA||Allergan||Consultant or Advisor||Current|
|Medtronic||Consultant or Advisor||Current|
EDUCATION COUNCIL DISCLOSURES:
COI REVIEW WORKGROUP DISCLOSURES:
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by view the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Estimated time to complete this activity: 2.00 hours
Release Date: May, 2023
Expiration Date: May, 2024
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation